Wagner, A.D., Grabsch, H.I., Mauer, M., Marreaud, S., Caballero, C., Thuss-Patience, P., et al. (2019) EORTC-1203-GITCG—The “INNOVATION”-Trial: Effect of Chemotherapy Alone versus Chemotherapy plus Trastuzumab, versus Chemotherapy plus Trastuzumab plus Pertuzumab, in the Perioperative Treatment of HER2 Positive, Gastric and Gastroesophageal Junction Adenocarcinoma on Pathologic Response Rate: A Randomized Phase II-Intergroup Trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer Group. BMC Cancer, 19, Article No. 494.
https://doi.org/10.1186/s12885-019-5675-4

has been cited by the following article:

• TITLE: Current Status and Research Progress of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

  AUTHORS: Junjian Liu, Tian Wei, Zhiping Xiang, Yinlu Ding

  KEYWORDS: Locally Advanced Gastric Cancer, Adjuvant Chemotherapy, Neoadjuvant Chemotherapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 30, 2023

  ABSTRACT: Gastric cancer is one of the most common malignant tumours worldwide, with a high degree of malignancy and a poor prognosis. While early gastric cancer can be cured by surgical treatment, locally advanced gastric cancer requires neoadjuvant therapy to shrink the tumour, suppress potential metastases, achieve down-staging, and provide patients with the opportunity for radical surgery to prolong their survival. This article reviews the current status and progress of neoadjuvant chemotherapy for locally advanced gastric cancer.